Our previous in silico investigation using this screen indicated that lung adenocarcinoma cell lines harboring KRAS mutations are more sensitive to farnesyl-transferase inhibitors than those with wild-type KRAS [23]. This evidence concerns the gene KRAS and lung adenocarcinoma.